Table 2 First-line phase 3 trials in EGFR exon 20 insertion NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Primary endpoint |
|---|---|---|---|
PAPILLON | NCT04538664 | Amivantamab with chemotherapy vs chemotherapy alone | PFS: endpoint met |
EXCLAIM-2 | NCT04129502 | Mobocertinib vs chemotherapy | PFS: endpoint not met |